ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Efficacy and related factors of levonorgestrel-releasing intrauterine system combined with metformin in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial cancer: A retrospective cohort study.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and related factors of levonorgestrel-releasing intrauterine system combined with metformin in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial cancer: A retrospective cohort study.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo compare the efficacy of the levonorgestrel-releasing intrauterine system combined with metformin versus oral progestin combined with metformin in fertility-preserving treatment for patients with atypical endometrial hyperplasia and early endometrial cancer, and to analyze related factors affecting efficacy.
methodsFrom January 2015 to December 2023, clinical data of patients with atypical endometrial hyperplasia or early endometrial cancer were retrospectively analyzed. Patients were divided into a study group and a control group based on treatment method. Complete remission rate, remission time, recurrence rate, pregnancy outcomes, and adverse reactions were compared between groups. Multivariate logistic regression was used to identify factors associated with complete remission, recurrence, and pregnancy.
resultsPost-treatment endometrial thickness decreased in both groups compared with pre-treatment levels, with a greater reduction in the study group than the control group. Compared with the control group, the study group demonstrated a higher complete remission rate at 3, 6, 9, and 12 months, shorter time to onset and time to complete remission, lower recurrence rate, higher pregnancy and live birth rates, and lower incidence of adverse reactions. Multivariate logistic regression analysis identified age 35 years or older, body mass index (BMI) of 28 or greater, polycystic ovary syndrome, and pathologic type of endometrial cancer as risk factors for complete remission. BMI of 28 or greater and pathologic type of endometrial cancer were risk factors for recurrence. Age 35 years or older and BMI 28 or greater were risk factors for pregnancy. BMI stratification analysis demonstrated that patients with lower BMI achieved better treatment outcomes.
conclusionsThis retrospective study preliminarily suggests that the levonorgestrel-releasing intrauterine system combined with metformin shows a trend toward better treatment response in fertility-preserving treatment, manifested by higher complete remission rates, shorter time to remission, lower recurrence rates, and favorable pregnancy outcomes. In addition, obesity, age of 35 years or older, polycystic ovary syndrome, and pathologic type of endometrial cancer were identified as factors influencing treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.